Plasmapheresis Filtration with Plasma Exchange Therapy (TPE) Could Benefit Patients with Covid-19

Overview

The mitigation of morbidity risk in patients with COVID-19 infection in the progression of acute respiratory distress syndrome (ARDS) related to severe respiratory tract damage with the high blood level of inflammatory markers as Cytokines IL-6 is an essential goal of contemporary treatment these patients in ICU environment. The Plasma Exchange therapy (TPE) with continuous hemofiltration (CHF) reduced level IL-6 and other cytokines in patients with different critical pathologies as fulminant liver damage, autoimmune inflammation, neurological and infectious diseases.

Summary

The severe damage of the lung tissue can result in acute respiratory distress syndrome (ARDS), which can further precipitate septic shock. The possible high mortality rate of COVID-19 can be connected to the increasing of Th17 cells activity mainly stimulated by IL-6 and IL-23. Removing IL-6 and IL-23 can improve the COVID-19th outcomes.

Author Comments

Dr. Sergey Zhuplatov, MD, PhD
Dr. Sergey Zhuplatov, MD, PhD
Sanofi Aventis
Global Clinical Research Director
Internal Medicine, Endocrinology, Cardiology
Southampton, PA | United States
I hope this article will help in the reduction of COVID-19 mortality rate.Dr. Sergey Zhuplatov, MD, PhD

Resources

DOI:
https://doi.org/10.19080/JAICM.2020.10.555798.

Removal of Endotoxins and Cytokines by Plasmapheresis Filtration with Plasma Exchange Therapy (TPE) Could Benefit Patients with Covid-19 in Critical Condition.

J Anest & Inten Care Med.

J Anest & Inten Care Med 10(5): JAICM.MS.ID.555798 (2020). DOI:10.19080/JAICM.2020.10.555798.

AbstractBackground: The COVID-19 pandemic originated in Wuhan, China is rapidly and continuously spreading globally and can result in significant severe respiratory morbidity and mortality. The severe damage of the lung tissue can result in acute respiratory distress syndrome (ARDS), which can further precipitate septic shock. These two complications are the major contributors to the intensive care unit (ICU) care and mortality from COVID-19 in patients older than 60 years, with smoking history, and comorbid medical conditions. The possible high mortality rate of COVID-19 can be connected to the increasing of Th17 cells activity mainly stimulated by IL-6 and IL-23. Discussion: The mitigation of morbidity risk in patients with COVID-19 infection in the progression of acute respiratory distress syndrome (ARDS) related to severe respiratory tract damage with the high blood level of inflammatory markers as Cytokines IL-6 is an essential goal of contemporary treatment these patients in ICU environment. The Plasma Exchange therapy (TPE) with continuous hemofiltration (CHF) reduced level IL-6 and other cytokines in patients with different critical pathologies as fulminant liver damage, autoimmune inflammation, neurological and infectious diseases. Conclusion: CHF with TPE treatment can be one of the ways of concomitant therapy in the standard of care for COVID-19 infection patients with developing respiratory distress syndrome. However, further investigations are necessary in order to corroborate this successful therapy.Keywords: COVID-19; Cytokines storm; IL-6; ARDS; Plasmapheresis; TPE; Plasma exchange therapy; Hemofiltration Abbreviations: ASFA: The American Society for Apheresis; COVID-19: Coronavirus Disease 2019; ICU: Intensive Care Unit; ARDS: Respiratory Distress Syndrome; CRS: The Systemic Inflammatory Response; TPE: Therapeutic Plasma Exchange; CHF: Continuous Hemofiltration; CHDF: Continuous Hemodiafiltration; PF: Plasmafiltration; IL-16: Interleukin-16; IL-23: Interleukin-23; Th17 , Th-0: T- Helper Lymphocytes-17(0)
May 2020
71 Reads

Similar Publications